Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of ...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta ® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of ...
(RTTNews) - Novartis AG (NVS) said that an analysis of treatment-naive people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six years ...
Roche’s Ocrevus had been growing comfortably as the top choice for new multiple sclerosis patients without major concern over competition until Novartis launched an in-class rival, Kesimpta. Now, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback